DSS to Receive 53,000 Dr Ashleys Shares with 75,000 Contingent Shares
DSS, Inc., which holds 88.87% of Impact Biomedical on a fully diluted basis, will receive 53,000 Dr Ashleys Bio Labs shares at closing with 75,000 additional shares contingent on meeting funding obligations. The merger agreement extension pushes the deadline from March 31 to July 1, 2026.
1. Merger Agreement Amendment
The Merger and Share Exchange Agreement between Impact Biomedical and Dr Ashleys Bio Labs Limited, originally set to close by March 31, has been amended to extend the end date to July 1, 2026. This extension provides additional time to satisfy all closing conditions, including financing and regulatory approvals.
2. DSS's Share Allocation and Funding Obligations
Under the revised terms, Dr Ashleys Bio Labs will issue 169.5 million ordinary shares to its sole shareholder at closing. DSS, Inc., as the parent of Impact Biomedical and holder of 88.87% of its fully diluted shares, will receive 53,000 ordinary shares at closing and an additional 75,000 shares if it fulfills its funding obligations under the Transition Arrangement Agreement.
3. Impact on DSS's Ownership Structure
Upon closing, DSS will gain a direct equity stake in Dr Ashleys Bio Labs through its share entitlement, potentially enhancing its asset base. The contingent 75,000 shares offer upside if DSS meets funding milestones, which could influence its long-term valuation and investor perception.